WG
RPRX icon

Winton Group’s Royalty Pharma RPRX Stock Holding History

Winton Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
+22,800
New +$1.19M 0.04% 441
2025
Q4 		– Sell
-95,200
Closed -$3.36M – 1091
2025
Q3 		$3.36M Buy
+95,200
New +$3.45M 0.13% 223
2021
Q4 		– Sell
-70,707
Closed -$2.56M – 1337
2021
Q3 		$2.56M Buy
70,707
+15,797
+29% +$614K 0.14% 123
2021
Q2 		$2.25M Buy
+54,910
New +$2.34M 0.12% 144

Other funds holding RPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.28B AUM 47.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Winton Group's RPRX Position: Q2 2026 in Review

Winton Group opened a new position in Royalty Pharma (RPRX) in Q2 2026: 22,800 shares worth $1.28M. The stake represents 0.04% of the portfolio and ranks #441 among its holdings. This is a return to the name: Winton Group previously reported a position in RPRX as recently as Q3 2025.

Winton Group first reported a position in RPRX in Q2 2021 and has held it in 4 quarters since. The position peaked at $3.36M in Q3 2025. 372 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Winton Group held 22,800 shares of Royalty Pharma worth $1.28M as of Q2 2026.
  • Royalty Pharma was a new Winton Group position in Q2 2026.
  • Royalty Pharma made up 0.04% of Winton Group's portfolio in Q2 2026, its #441 holding.
  • Winton Group first reported a position in Royalty Pharma in Q2 2021 and has held it in 4 quarters since.
  • Winton Group's Royalty Pharma position peaked at $3.36M in Q3 2025.
  • 372 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.